Search Results

You are looking at 1 - 10 of 621 items for :

  • "vincristine" x
  • Refine by Access: all x
Clear All
Restricted access

Inadvertent intrathecal vincristine administration: a neurosurgical emergency

Case report

Maher Qweider, Joachim M. Gilsbach, and Veit Rohde

V incristine sulfate is an alkaloid that is widely used as a chemotherapeutic agent to treat patients with leukemia, Ewing sarcoma, neuroblastoma, and other malignant conditions. It is administered intravenously, often in combination with other antineoplastic drugs. Vincristine is a microtubule-depolymerizing drug that exerts its antineoplastic properties by arresting the mitotic cycle in the metaphase. It similarly attacks neurotubules, which explains why, among others, peripheral motor and sensory neuropathy are common side effects. These neuropathic

Restricted access

Response to vincristine of recurrent brain tumors in children

Jeffrey G. Rosenstock, Audrey E. Evans, and Luis Schut

S ince the advent of cancer chemotherapy, numerous agents have been tried in the treatment of intracranial neoplasms with initially disappointing results. More recently, individual cases and reports of small series have cited patient responses to methotrexate, 22, 23, 40 procarbazine, 13 vincristine (VCR), 1, 3, 10, 14, 16, 25, 26, 33 as well as the nitrosoureas, 28, 37, 39 used alone or in combination. 7–9 The chemotherapy trials have been recently reviewed. 4, 18 Based on the responses to VCR reported by several investigators, the Oncology and

Restricted access

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine

Darryl C. Longee, Henry S. Friedman, Robert E. Albright Jr., Peter C. Burger, W. Jerry Oakes, Joseph O. Moore, and S. Clifford Schold Jr.

T he role of chemotherapy in the treatment of recurrent gliomas remains unclear. 3, 10 A variety of agents have been used either alone or in combination, with response rates of 20% to 45% in most studies. 11, 17 The median duration of response in these studies is between 3 and 6 months, and it is unusual for patients with recurrent gliomas to survive more than 12 months. Cyclophosphamide and vincristine have demonstrated activity as single agents and in combination in the treatment of recurrent central nervous system (CNS) tumors of childhood; 4, 14, 19

Restricted access

Potentiation of vincristine effect in human and murine gliomas by calcium channel blockers or calmodulin inhibitors

Keizo Kaba, Eiichi Tani, Tatsuo Morimura, and Tsuyoshi Matsumoto

Recently, calcium channel blockers and calmodulin inhibitors have been found to enhance vincristine cytotoxicity, particularly in vincristine-resistant murine and human tumor cells. 19–25 Since vincristine has been widely used as a chemotherapeutic drug together with cell-cycle nonspecific agents for the treatment of human glioma, 4, 7, 10, 11, 15 the present study examines the effect of calcium channel blockers and calmodulin inhibitors on vincristine cytotoxicity for human and murine glioma cells. Materials and Methods Glioma Cells Five glioma cell lines

Restricted access

Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine

David C. Crafts, Victor A. Levin, Michael S. Edwards, Tana L. Pischer, and Charles B. Wilson

procarbazine. 5 This investigation was followed by a Phase II study of a combination of three drugs, procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea), and vincristine (PCV), which had proved to be as effective as BCNU (1, 3-bis(2-chloroethyl)-1-nitrosourea) against recurrent cerebral glioma. 3 The early results with medulloblastoma were so favorable that PCV was the standard chemotherapy for this tumor for more than 4 years. The results of our experience with the original PCV schedule, Series 1, and a recent modification of the original schedule, Series 2

Restricted access

Preoperative vincristine for an inoperable choroid plexus papilloma: a case discussion and review of the literature

Case report

Nii K. Addo, Ian D. Kamaly-Asl, Vivek A. Josan, Anna M. Kelsey, and Edward J. Estlin

extensively hypertrophied, tortuous, and elongated to facilitate the embolization technique. Therefore, there is currently no mainstay management that can be used to reduce tumor vascularity prior to surgery, independent of tumor size and behavior. We present the case of a 14-month-old boy with a very large CPP that was unsuitable for embolization. Preoperative vincristine caused a significant reduction in tumor volume, which subsequently enabled a successful total resection. Case Report History and Examination This 14-month-old boy with normal development

Restricted access

Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines

Jörg-Christian Tonn, Hans Kristian Haugland, Jaakko Saraste, Klaus Roosen, and Ole Didrik Laerum

methodological approaches have been used to study these phenomena. 31, 44 The confrontation assay, which cultures brain aggregates together with glioma spheroids, has been well characterized in the past and represents a reproducible and reliable in vitro system to investigate glioma invasion. 7, 8, 12 Besides gaining further insight into the functional mechanisms of tumor cell invasion the challenge for researchers is to eventually control invasive properties. The vinca alkaloids, for example vincristine (VCR), inhibit microtubule assembly, which leads to growth arrest in

Restricted access

Phase II study of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group

Tomokazu Aoki, Jun A. Takahashi, Tetsuya Ueba, Natsuo Oya, Masahiro Hiraoka, Kunihiko Matsui, Tsugiya Fukui, Yasuaki Nakashima, Masatsune Ishikawa, and Nobuo Hashimoto

government approval. Both BCNU and CCNU are also not available. Nimustine, which was developed as one of the chloroethylnitrosoureas, has been widely used for Japanese patients with malignant gliomas. 24 Combined treatment with ACNU plus vincristine or IFNβ has also been used in daily medical practice for the treatment of malignant gliomas. 13 , 28 The safety profiles of these treatments have been accepted. In 1998, a metaanalysis of published reports on the treatment of high-grade astrocytomas found some efficacy in the use of nitrosoureas, platinums, vincristine, and

Restricted access

Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas

Victor A. Levin, William M. Wara, Richard L. Davis, Pamela Vestnys, Kenneth J. Resser, Kathleen Yatsko, Stephen Nutik, Philip H. Gutin, and Charles B. Wilson

T he multimodality treatment of patients harboring primary malignant brain tumors is well established. 4, 18, 20 The nitrosoureas and procarbazine are the agents most widely used, 4, 10, 11, 14, 18–20 and both 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) are active against malignant gliomas. 6, 11, 13, 18, 20 Despite the known activity of these two treatments, however, no randomized study comparing their relative benefit has been reported. The

Restricted access

Chemotherapy as an adjunct in the initial management of cerebellar medulloblastomas

A preliminary report

Joan L. Venes, Sue McIntosh, Richard T. O'Brien, and Allen D. Schwartz

. Chemotherapy was begun 4 to 6 weeks after completion of radiation therapy at a time when peripheral blood counts indicated resolution of clinically significant bone marrow depression induced by radiation. After completion of radiation therapy, neurological evaluation and computerized tomography (CT) were carried out to evaluate the amount of residual tumor and the presence or absence of hydrocephalus. In some of the earlier cases, this initial assessment with CT was replaced by technetium brain scan. The patients then received intravenous vincristine sulfate (1.5 mg/sq m